ARCHIVE ISSUES – JUNE 2023

Precision Medicine Quarterly June 2023

Price of Precision: Patients, Oncologists Highlight Costs of Fighting for Access to Newest Drugs

Precision Oncology Marches on Amid Manufacturing Woes, Regulatory Debates, Guideline Limitations

Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology

The Impact of Structural Variants and Co-Occurring Variants on Cancer Therapy Prioritization

AI-Based Dx Could Enable Surgeons to Molecularly Classify Brain Tumors in Operating Room

Behavioral Nudges in Study Increase Germline Genetic Testing Referrals but Not Patient Uptake

Next Wave of KRAS G12C Inhibitors May Address Limits of First-Gen Drugs, AACR Studies Show

Next-Gen Cell Therapies Bedeviled by Regulatory Murkiness on Product Characterization, Manufacturing

Microbiome Therapeutics Find Their Footing in Cancer

A Review of the Many Facets of Standardized Variant Interpretation

Precision Targeting of Cancer Using CRISPR: An Introduction to Precision KLIPP Therapy

Evolving Landscape of HER2‑Low Breast Cancer: New Diagnosis and Treatment Paradigm Shift

Integrated Multi-Omics Approach Driven by Artificial Intelligence to Realize Whole‑Course Management of Cancer

Advocating for Regulatory Approval to Improve Care for Patients With Dihydropyrimidine Dehydrogenase Deficiency

BACK TO ARCHIVE